ResearchDx Hires New Staff to Senior Management Team

Research Dx is pleased to announce two new additions to the senior management team. Stephen Jones as Chief Operating Officer and Tom Li as VP Business Development. Stephen Jones Chief Operating Officer  Steve Jones is the COO for ResearchDx responsible for end-to-end oversight of all functions including laboratory operations, business development and research and development. Prior […]

Read More

Genentech releases new video discussing biomarker testing evolution

Genentech has released a new video discussing the evolution of biomarker testing for NSCLS treatment. The video features a seasoned panel of industry experts discussing the topic, including ResearchDx’s own Chief Medical Officer Shelly Gunn. The video is published on Genetech’s website, the link of which is provided below: Resources for biomarker testing for NSCLC […]

Read More

INOVIQ (ASX:IIQ) Partners with ResearchDx to Develop SubB2M-Based Cancer Tests in the US

Originally sourced from CMOCRO   INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the […]

Read More

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth

Originally sourced from Business Wire   NEW YORK–(BUSINESS WIRE)–Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited […]

Read More

ResearchDx Will Be Exhibiting At AMP 2021

ResearchDx will be exhibiting at AMP 2021 . Please visit us at booth #327. Additionally, our Chief Medical Officer Dr. Shelly Gunn will present the abstract: “Identification of a Novel Large F13A1 Intragenic Deletion by Targeted Next Generation Sequencing in a Patient with Factor X111 Deficiency.” Please call us at 760 473 4295 to set […]

Read More

Hemophilia—The Royal Disease

Our CAP/CLIA certified lab, PacificDx is partnered with CHOC (Children’s Hospital of Orange County) to identify rare inherited blood disorders in infants and mothers to improve their quality of life. Written by Amanda Nguyen (March 2021) ____________________________________________________________________________________________________________________________________________________ The last royal family of Russia was speculated to be plagued with the “royal bleeding disease” passed down […]

Read More

trio-smart: The New Breathtaking Technology

PacificDX is the only lab certified to run trio-Smart™, a breath test developed by Gemelli™. Along with measuring the standard H2, CH4 and CO2 levels, trio-smart™ is the only BT that also measures hydrogen sulfide. You are at a fancy dinner party wearing your favorite dress. After the delicious meal, you are conversing with an […]

Read More

ResearchDx Partners with Lucid Diagnostics for First DNA Methylation Test for Barrett’s Esophagus

As Lucid Diagnostics’ commercial diagnostic laboratory partner, the new EsoGuard esophageal DNA laboratory-developed test (LDT) was developed and completed CLIA and CAP certification at ResearchDx’s premier molecular laboratory, PacificDx. The first of its kind, this non-invasive DNA test was designed to detect the presence of dysplastic and non-dysplastic Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC) […]

Read More

Negative Gluten ID Test Results can ‘Rule Out’ Celiac Disease in High Risk Populations

Brief:  First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]

Read More